Plant Name: Solanum nigrum
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| CHRM1; CHRM2; CHRM3; CHRM4; CHRM5; GPR35; ADORA3; ADORA2A; ADORA1; ADRA2C; ADRA2A; DRD4; | |
| TSHR; NPSR1; CXCR1; NMUR2; | |
| ALPL; RECQL; PLA2G1B; TDP1; APOBEC3G; CTDSP1; TERT; PKM; PIK3CG; ADK; GALK1; PIK3R1; GLO1; HPGD; PGD; MPO; HSD17B1; AKR1B1; HSD17B2; HSD17B10; ALOX15; ALDH1A1; ALOX12; GFER; AKR1B10; NOX4; USP2; TNKS; PARP1; TNKS2; PYGL; APEX1; CD38; POLB; | |
| PTPN1; | |
| ACHE; GAA; | |
| CFTR; | |
| KCNH2; | |
| BCL2; | |
| TOP2A; | |
| NEK6; AKT1; MET; CAMK2B; GSK3B; CSNK2A1; DAPK1; SYK; NEK2; AXL; FLT3; SRC; IGF1R; PTK2; AURKB; DYRK1A; INSR; KDR; CDK1; MAPK1; MAPK14; PIM1; NUAK1; ALK; MYLK; CDK6; PKN1; | |
| CA14; CA5A; CA3; CA5B; CA1; CA12; CA9; CA7; CA4; CA6; CA2; | |
| AR; | |
| ESRRA; | |
| ESR1; ESR2; | |
| KDM4E; | |
| MAOA; PTGS2; ALOX5; TYR; XDH; | |
| CASP7; CASP1; | |
| MMP13; MMP12; MMP3; MMP2; MMP14; MMP9; MMP1; | |
| BACE1; | |
| AHR; STAT6; HIF1A; NFKB1; TP53; | |
| DNMT1; | |
| FUT7; | |
| SLC28A2; SLC28A1; SLC28A3; | |
| ABCC1; ABCB1; ABCG2; | |
| LMNA; MAPT; THPO; SIGMAR1; HTT; RAB9A; NPC1; APP; TTR; | |
| L3MBTL1; SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| DNA methyltransferase | DNMT1 | DNA (cytosine-5)-methyltransferase 1 | P26358 | CHEMBL1993 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | APOBEC3G | DNA dC->dU-editing enzyme APOBEC-3G | Q9HC16 | CHEMBL1741217 |
| Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | PIK3CG | PI3-kinase p110-gamma subunit | P48736 | CHEMBL3267 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | GALK1 | Galactokinase | P51570 | CHEMBL1293257 |
| Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP14 | Matrix metalloproteinase 14 | P50281 | CHEMBL3869 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Potassium channels | KCNH2 | HERG | Q12809 | CHEMBL240 |
| Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | DYRK1A | Dual-specificity tyrosine-phosphorylation regulated kinase 1A | Q13627 | CHEMBL2292 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | MAPK14 | MAP kinase p38 alpha | Q16539 | CHEMBL260 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
| Protein Kinase | MYLK | Myosin light chain kinase, smooth muscle | Q15746 | CHEMBL2428 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| Small molecule receptor (family A GPCR) | CHRM1 | Muscarinic acetylcholine receptor M1 | P11229 | CHEMBL216 |
| Small molecule receptor (family A GPCR) | CHRM2 | Muscarinic acetylcholine receptor M2 | P08172 | CHEMBL211 |
| Small molecule receptor (family A GPCR) | CHRM3 | Muscarinic acetylcholine receptor M3 | P20309 | CHEMBL245 |
| Small molecule receptor (family A GPCR) | CHRM4 | Muscarinic acetylcholine receptor M4 | P08173 | CHEMBL1821 |
| Small molecule receptor (family A GPCR) | CHRM5 | Muscarinic acetylcholine receptor M5 | P08912 | CHEMBL2035 |
| Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | SIGMAR1 | Sigma opioid receptor | Q99720 | CHEMBL287 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.728E-12 | 4.324E-10 | ADORA2A, AURKB, CA2, CA7, CFTR, HIF1A, HTT, MAPK1, MAPK14, NEK2, NPC1, NPSR1, PLA2G1B, PTGS2, SYK, TNKS, TNKS2 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.419E-12 | 8.181E-10 | APOBEC3G, AR, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, DNMT1, ESR1, ESR2, ESRRA, GLO1, L3MBTL1, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP9, PARP1, PTPN1, TNKS, TP53 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 4.141E-12 | 9.801E-10 | ABCB1, ABCC1, ABCG2, ADK, AKT1, ALK, AURKB, AXL, CAMK2B, CDK1, CDK6, CFTR, CSNK2A1, DAPK1, DYRK1A, FLT3, GALK1, GSK3B, IGF1R, INSR, KDR, MAPK1, MAPK14, MET, MYLK, NEK2, NEK6, NUAK1, PIK3CG, PIM1, PKM, PKN1, PTK2, PYGL, RECQL, SRC, SYK, TOP2A, TP53 |
| BP | GO:0050896; response to stimulus | GO:0007197; adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway | 2.468E-11 | 4.714E-09 | CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| MF | GO:0060089; molecular transducer activity | GO:0016907; G-protein coupled acetylcholine receptor activity | 2.468E-11 | 4.714E-09 | CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 3.455E-11 | 6.172E-09 | AKT1, AURKB, BCL2, CAMK2B, CDK1, DYRK1A, GSK3B, MAPK1, MAPK14, NEK6, PKN1, SRC, SYK, TNKS |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.742E-11 | 6.571E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.990E-11 | 8.556E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, NOX4 |
| BP | GO:0050896; response to stimulus | GO:0007207; phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway | 1.472E-10 | 2.272E-08 | CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 2.870E-10 | 4.032E-08 | AKT1, ALK, AURKB, CAMK2B, CDK1, CDK6, CSNK2A1, DAPK1, DYRK1A, GSK3B, MAPK1, MAPK14, MYLK, NEK2, NEK6, NUAK1, PIK3CG, PIM1, PKN1, SYK |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.891E-10 | 4.036E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, MPO, NOX4, PTGS2, SRC |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 4.138E-10 | 5.632E-08 | AKT1, BCL2, CAMK2B, CDK1, CSNK2A1, DYRK1A, GSK3B, MAPK1, PKN1, TNKS |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.310E-09 | 3.677E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.808E-09 | 4.166E-07 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, XDH |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 9.019E-09 | 9.442E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.657E-08 | 1.640E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.872E-08 | 1.836E-06 | CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 4.905E-08 | 4.307E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 7.516E-08 | 6.343E-06 | ABCC1, ADORA1, ADORA2A, ADORA3, ADRA2A, ADRA2C, ALK, APP, AXL, BACE1, CFTR, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD4, FLT3, GPR35, IGF1R, INSR, KDR, MET, MMP14, NPC1, NPSR1, SIGMAR1, SLC28A1, SLC28A2, SLC28A3, TSHR |
| BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 8.669E-08 | 7.232E-06 | MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP9, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.007E-07 | 8.306E-06 | ALOX12, ALOX15, ALOX5, HPGD, PTGS2 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 1.245E-07 | 1.007E-05 | HIF1A, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP9, PLA2G1B |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 1.418E-07 | 1.131E-05 | AURKB, MAPK1, NEK2, TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 1.715E-07 | 1.324E-05 | ADRA2A, ADRA2C, AKT1, AXL, MAPK1, PIK3CG, PIK3R1, SRC, SYK |
| MF | Unclassified; | GO:0004872; receptor activity | 2.047E-07 | 1.531E-05 | ADORA1, ADORA2A, ADORA3, ADRA2A, ADRA2C, AHR, ALK, AR, AXL, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CXCR1, DRD4, ESR1, ESR2, ESRRA, FLT3, GPR35, HPGD, IGF1R, INSR, KCNH2, KDR, MET, NMUR2, NPC1, NPSR1, SIGMAR1, TSHR |
| BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 2.967E-07 | 2.084E-05 | AHR, AXL, BCL2, CSNK2A1, DRD4, DYRK1A, ESR1, GSK3B, MMP14, SRC, TOP2A, TP53, USP2 |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 3.147E-07 | 2.196E-05 | HIF1A, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP9 |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 4.480E-07 | 2.983E-05 | AKT1, INSR, MAPK14, MAPT, NOX4, PTGS2, TP53, XDH |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 6.111E-07 | 3.879E-05 | ADORA1, ADORA2A, BCL2, CA2, CA7, HTT, KDR, NPSR1, PARP1, PLA2G1B, SRC |
| BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 6.455E-07 | 4.062E-05 | MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP9 |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 6.705E-07 | 4.208E-05 | ABCB1, CA2, CA7, CFTR |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 1.336E-06 | 7.902E-05 | ADK, AHR, AKR1B1, AKR1B10, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, APOBEC3G, APP, AR, AURKB, BCL2, CA1, CA2, CA3, CA7, CAMK2B, CASP1, CASP7, CDK1, CDK6, CFTR, CSNK2A1, FLT3, GALK1, GFER, GLO1, GSK3B, HIF1A, HPGD, HSD17B1, HTT, LMNA, MAPK1, MAPK14, MAPT, MMP14, MYLK, NEK2, NEK6, NFKB1, PGD, PIK3CG, PIK3R1, PIM1, PKM, PKN1, PLA2G1B, PTK2, PTPN1, PYGL, RAB9A, SMN1, SMN2, SRC, STAT6, SYK, TNKS, TNKS2, TP53, TYR, XDH |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.360E-06 | 8.018E-05 | AKT1, BCL2, HIF1A, LMNA, PTGS2, SRC, TERT, TP53 |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.515E-06 | 8.749E-05 | IGF1R, INSR, KDR, PTK2, SRC, SYK |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.562E-06 | 8.996E-05 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 2.072E-06 | 1.166E-04 | ADK, AHR, AKR1B1, AKT1, ALOX5, APEX1, AR, AURKB, BCL2, CAMK2B, CASP7, CDK1, CDK6, CSNK2A1, CTDSP1, DNMT1, DYRK1A, ESR1, ESR2, ESRRA, GSK3B, HIF1A, HPGD, HTT, L3MBTL1, LMNA, MAPK1, MAPK14, NEK2, NEK6, NFKB1, NUAK1, PARP1, PIM1, PKN1, POLB, RECQL, SMN1, SMN2, SRC, STAT6, TERT, TNKS, TOP2A, TP53, USP2 |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 2.104E-06 | 1.178E-04 | AKT1, BCL2, MAPT, PTPN1, TP53 |
| BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 2.458E-06 | 1.348E-04 | MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP9 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 2.637E-06 | 1.439E-04 | AXL, INSR, MET, NOX4, PIK3CG, PIK3R1, PTK2, SRC, THPO |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 3.093E-06 | 1.667E-04 | ADORA1, ADORA2A, ADORA3, ADRA2A, ADRA2C, ALK, AXL, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CXCR1, DRD4, FLT3, GPR35, HPGD, IGF1R, INSR, KDR, MET, NMUR2, NPC1, NPSR1, SIGMAR1, TSHR |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 4.206E-06 | 2.217E-04 | AHR, CSNK2A1, HIF1A, KDR, MAPT |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 4.357E-06 | 2.271E-04 | AR, CYP3A4, ESR1, ESR2, ESRRA, HSD17B1, NPC1 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 4.359E-06 | 2.271E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 5.740E-06 | 2.907E-04 | ADRA2A, ADRA2C, AKT1, INSR, SRC |
| BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 5.740E-06 | 2.907E-04 | AURKB, MAPK1, NEK2, TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 7.172E-06 | 3.558E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1, STAT6 |
| BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 8.460E-06 | 4.103E-04 | AKT1, BCL2, HIF1A, MMP9, PTGS2, PTPN1, SRC |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 8.668E-06 | 4.194E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 1.039E-05 | 4.851E-04 | APP, CDK1, MAPK1, MAPK14, PARP1, PIK3R1, PTGS2 |
| MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 1.090E-05 | 5.062E-04 | ABCG2, ACHE, ADRA2A, ADRA2C, AKT1, APOBEC3G, BCL2, CAMK2B, FLT3, HPGD, KCNH2, MAPT, NFKB1, PTGS2, PYGL, TERT, TOP2A, TYR, XDH |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.361E-05 | 6.215E-04 | ABCC1, ADORA1, ADRA2A, CA2, CA4, CA9, CHRM3, HPGD, TSHR |
| MF | GO:0005215; transporter activity | GO:0008559; xenobiotic transmembrane transporting ATPase activity | 1.508E-05 | 6.786E-04 | ABCB1, ABCC1, ABCG2 |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 1.508E-05 | 6.786E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | Unclassified; | GO:0032845; negative regulation of homeostatic process | 1.536E-05 | 6.881E-04 | ADORA1, ADRA2A, BCL2, CD38, PARP1, SRC, TNKS, TNKS2 |
| MF | GO:0003824; catalytic activity | GO:0004712; protein serine/threonine/tyrosine kinase activity | 1.670E-05 | 7.469E-04 | AKT1, AURKB, DYRK1A, MAPK1, MAPK14 |
| BP | GO:0051179; localization | GO:0046326; positive regulation of glucose import | 1.879E-05 | 8.298E-04 | AKT1, INSR, MAPK14, PIK3R1, TERT |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 1.883E-05 | 8.301E-04 | AXL, KDR, MAPK14, PIK3R1, PTK2, SRC |
| BP | GO:0009987; cellular process | GO:0071216; cellular response to biotic stimulus | 2.065E-05 | 8.975E-04 | AXL, CASP1, GSK3B, MAPK14, NFKB1, SRC, SYK, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0043536; positive regulation of blood vessel endothelial cell migration | 2.107E-05 | 9.119E-04 | AKT1, HIF1A, KDR, MAPK14, PTGS2 |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 2.174E-05 | 9.374E-04 | HPGD, MMP2, MMP9, TERT |
| BP | GO:0008152; metabolic process | GO:0050995; negative regulation of lipid catabolic process | 2.174E-05 | 9.374E-04 | ADORA1, ADRA2A, AKT1, PIK3CG |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 2.400E-05 | 1.015E-03 | ADRA2A, ADRA2C, DRD4 |
| MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 2.932E-05 | 1.211E-03 | ADORA1, ADORA2A, ADRA2A, ADRA2C, AHR, AXL, BCL2, HIF1A, NFKB1, PIK3R1, TOP2A, TP53, TTR, TYR |
| MF | GO:0003824; catalytic activity | GO:0004222; metalloendopeptidase activity | 2.953E-05 | 1.218E-03 | MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP9 |
| BP | GO:0050896; response to stimulus | GO:0006954; inflammatory response | 3.115E-05 | 1.275E-03 | ADORA1, ADORA2A, ADORA3, AKT1, ALOX15, AXL, CXCR1, NFKB1, NOX4, PIK3CG, POLB, PTGS2, SYK |
| BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 3.580E-05 | 1.439E-03 | ADORA2A, APP, MAPT |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 3.580E-05 | 1.439E-03 | ADORA1, ADORA2A, ADORA3 |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 3.580E-05 | 1.439E-03 | INSR, KDR, SYK |
| MF | Unclassified; | GO:0032403; protein complex binding | 3.856E-05 | 1.524E-03 | ACHE, ADORA1, ADRA2A, APEX1, FLT3, IGF1R, INSR, KDR, MMP12, MMP13, MMP14, MMP9, PIK3R1, PKM, PTPN1, SRC, SYK, TSHR |
| BP | GO:0050896; response to stimulus | GO:0071320; cellular response to cAMP | 3.961E-05 | 1.560E-03 | APEX1, APP, CFTR, NOX4, PIK3CG |
| BP | GO:0051179; localization | GO:0006869; lipid transport | 4.114E-05 | 1.617E-03 | ABCB1, ABCC1, ABCG2, CFTR, DRD4, HTT, NMUR2, NPC1, PLA2G1B, SIGMAR1 |
| CC | GO:0044464; cell part | GO:0005739; mitochondrion | 4.650E-05 | 1.808E-03 | AKT1, APEX1, BCL2, CA5A, CA5B, CASP1, CDK1, CYP1A1, CYP1B1, ESR2, GFER, GSK3B, HSD17B10, MAOA, MAPK1, MAPK14, MMP2, MPO, NFKB1, NOX4, PARP1, PKM, SRC, TP53 |
| BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 5.063E-05 | 1.948E-03 | PARP1, SRC, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 5.063E-05 | 1.948E-03 | APP, GSK3B, IGF1R, PARP1 |
| BP | GO:0051179; localization | GO:0042908; xenobiotic transport | 5.085E-05 | 1.953E-03 | ABCB1, ABCC1, ABCG2 |
| BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 5.768E-05 | 2.152E-03 | BCL2, NOX4, PARP1, POLB, TP53 |
| BP | GO:0032502; developmental process | GO:0045597; positive regulation of cell differentiation | 5.782E-05 | 2.152E-03 | ADRA2C, AKT1, APP, AR, AXL, BCL2, CA2, CAMK2B, HIF1A, KDR, MAPK14, MAPT, MMP14, NFKB1, PARP1, PTGS2, SYK, TERT, THPO |
| BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 5.831E-05 | 2.152E-03 | SLC28A2, SLC28A3 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 5.831E-05 | 2.152E-03 | APEX1, POLB |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 5.831E-05 | 2.152E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 5.831E-05 | 2.152E-03 | ESR1, ESR2 |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 5.831E-05 | 2.152E-03 | SLC28A1, SLC28A3 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 5.831E-05 | 2.152E-03 | ALOX12, ALOX15 |
| MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 5.831E-05 | 2.152E-03 | SLC28A2, SLC28A3 |
| BP | GO:0065007; biological regulation | GO:0010952; positive regulation of peptidase activity | 5.959E-05 | 2.195E-03 | APP, CASP1, CASP7, DAPK1, MAPK14, MAPT, MMP14, XDH |
| BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 6.458E-05 | 2.356E-03 | AKT1, AURKB, CSNK2A1, DYRK1A, L3MBTL1, MAPK14, NUAK1, TP53 |
| MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 6.771E-05 | 2.453E-03 | AXL, IGF1R, INSR, PIK3R1 |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 6.901E-05 | 2.488E-03 | AR, CDK1, CFTR, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
| BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 6.952E-05 | 2.490E-03 | AR, CYP19A1, ESR1 |
| MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 6.952E-05 | 2.490E-03 | IGF1R, INSR, PIK3R1 |
| MF | GO:0005488; binding | GO:0034452; dynactin binding | 6.952E-05 | 2.490E-03 | GSK3B, HTT, MAPT |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 8.864E-05 | 3.078E-03 | AKT1, CYP1A2, MAPK1, MMP9 |
| BP | GO:0008283; cell proliferation | GO:0033598; mammary gland epithelial cell proliferation | 9.218E-05 | 3.181E-03 | ESR1, MAPK1, STAT6 |
| BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 1.078E-04 | 3.644E-03 | ADORA1, ADORA2A, DRD4, TOP2A, TP53, USP2 |
| BP | Unclassified; | GO:0045907; positive regulation of vasoconstriction | 1.139E-04 | 3.837E-03 | ADRA2C, AKT1, CD38, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 1.192E-04 | 3.986E-03 | CYP19A1, HSD17B1, HSD17B2 |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 1.192E-04 | 3.986E-03 | ADORA2A, CA2, CA7 |
| BP | GO:0050896; response to stimulus | GO:0009612; response to mechanical stimulus | 1.319E-04 | 4.365E-03 | AKT1, CASP1, MAPK14, MMP14, MPO, NFKB1, PTGS2, SRC |
| BP | GO:0051179; localization | GO:0051926; negative regulation of calcium ion transport | 1.408E-04 | 4.625E-03 | ADRA2A, BCL2, DRD4, GPR35, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0006081; cellular aldehyde metabolic process | 1.408E-04 | 4.625E-03 | AKR1B10, ALDH1A1, CYP1B1, GLO1, PGD |
| MF | Unclassified; | GO:0140097; catalytic activity, acting on DNA | 1.415E-04 | 4.641E-03 | APEX1, DNMT1, PARP1, POLB, RECQL, TDP1, TERT, TOP2A |
| BP | GO:0032502; developmental process | GO:0060065; uterus development | 1.508E-04 | 4.923E-03 | CYP19A1, ESR1, SRC |
| BP | GO:0040011; locomotion | GO:0014911; positive regulation of smooth muscle cell migration | 1.611E-04 | 5.204E-03 | BCL2, NOX4, SRC, TERT |
| BP | GO:0065007; biological regulation | GO:0045124; regulation of bone resorption | 1.611E-04 | 5.204E-03 | CA2, CD38, SRC, SYK |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 1.741E-04 | 5.474E-03 | SLC28A1, SLC28A3 |
| BP | GO:0008152; metabolic process | GO:0006059; hexitol metabolic process | 1.741E-04 | 5.474E-03 | AKR1B1, GALK1 |
| BP | GO:0051179; localization | GO:0099039; sphingolipid translocation | 1.741E-04 | 5.474E-03 | ABCB1, ABCC1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.741E-04 | 5.474E-03 | CA2, CA7 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 1.741E-04 | 5.474E-03 | SLC28A1, SLC28A3 |
| BP | GO:0008152; metabolic process | GO:0045913; positive regulation of carbohydrate metabolic process | 1.745E-04 | 5.474E-03 | AKT1, HIF1A, INSR, NFKB1, SRC |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 1.741E-04 | 5.474E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.741E-04 | 5.474E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.741E-04 | 5.474E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.741E-04 | 5.474E-03 | ADRA2A, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.741E-04 | 5.474E-03 | ALOX12, ALOX15 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 1.741E-04 | 5.474E-03 | ADORA1, ADORA2A |
| BP | GO:0065007; biological regulation | GO:0043393; regulation of protein binding | 1.859E-04 | 5.783E-03 | APP, AURKB, BCL2, GSK3B, MET, MMP9, SRC, TERT |
| BP | GO:0065007; biological regulation | GO:0048167; regulation of synaptic plasticity | 1.867E-04 | 5.791E-03 | ADORA1, ADORA2A, APP, CAMK2B, CD38, MAPK1, PTGS2 |
| BP | GO:0002376; immune system process | GO:0002521; leukocyte differentiation | 1.873E-04 | 5.798E-03 | AXL, BCL2, FLT3, FUT7, GLO1, MAPK14, MMP9, PARP1, PIK3R1 |
| BP | GO:0051179; localization | GO:0070198; protein localization to chromosome, telomeric region | 1.874E-04 | 5.798E-03 | TERT, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:0001101; response to acid chemical | 1.930E-04 | 5.952E-03 | AKR1B1, AKT1, CD38, DNMT1, HSD17B2, KDR, MMP2, PTGS2, SRC, TP53 |
| BP | GO:0009987; cellular process | GO:0097194; execution phase of apoptosis | 1.995E-04 | 6.117E-03 | AKT1, CASP1, CASP7, PTK2 |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 2.001E-04 | 6.119E-03 | GSK3B, HIF1A, HTT, NUAK1, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0007399; nervous system development | 2.028E-04 | 6.135E-03 | ACHE, ADORA1, CHRM1, CHRM2, CHRM3, DYRK1A, SIGMAR1, SMN1, SMN2, TSHR |
| BP | GO:0065007; biological regulation | GO:0060249; anatomical structure homeostasis | 2.218E-04 | 6.633E-03 | AKR1B1, APEX1, BCL2, GAA, HIF1A, NOX4, PARP1, SRC, TERT |
| BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 2.272E-04 | 6.768E-03 | ADRA2A, AKT1, HIF1A, INSR, NOX4, PIK3R1, PYGL |
| BP | GO:0009987; cellular process | GO:2000811; negative regulation of anoikis | 2.294E-04 | 6.769E-03 | BCL2, PTK2, SRC |
| BP | GO:0032501; multicellular organismal process | GO:0045986; negative regulation of smooth muscle contraction | 2.294E-04 | 6.769E-03 | ADORA1, ADRA2C, PTGS2 |
| CC | GO:0044464; cell part | GO:0030673; axolemma | 2.294E-04 | 6.769E-03 | ADORA1, ADORA2A, MAPT |
| BP | GO:0008152; metabolic process | GO:0031331; positive regulation of cellular catabolic process | 2.380E-04 | 7.014E-03 | ADRA2A, AKT1, CDK1, DAPK1, GSK3B, HIF1A, HTT, INSR, KDR, PTK2, PTPN1 |
| BP | GO:0022610; biological adhesion | GO:0033628; regulation of cell adhesion mediated by integrin | 2.440E-04 | 7.171E-03 | CYP1B1, PIK3CG, PTK2, SYK |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 2.455E-04 | 7.205E-03 | BCL2, CAMK2B, CDK1, CFTR, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, HSD17B2, NOX4, PTGS2, RAB9A, SIGMAR1, SLC28A3 |
| CC | GO:0044464; cell part | GO:0005764; lysosome | 2.685E-04 | 7.764E-03 | AKR1B1, AKR1B10, GAA, MPO, NPC1, PIK3CG, RAB9A, SRC, TYR |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 2.770E-04 | 7.937E-03 | CYP2C19, CYP2C8, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 2.770E-04 | 7.937E-03 | AURKB, CDK1, PKN1 |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 2.944E-04 | 8.391E-03 | AXL, CDK1, CSNK2A1, FLT3, PKM |
| BP | GO:0009987; cellular process | GO:0001961; positive regulation of cytokine-mediated signaling pathway | 3.237E-04 | 9.155E-03 | AXL, CASP1, HIF1A, MMP12 |
| BP | GO:0009987; cellular process | GO:0010822; positive regulation of mitochondrion organization | 3.294E-04 | 9.304E-03 | BCL2, GSK3B, HIF1A, HTT, KDR, MMP9, TP53 |
| BP | GO:0008152; metabolic process | GO:0051000; positive regulation of nitric-oxide synthase activity | 3.306E-04 | 9.324E-03 | AKT1, HIF1A, TERT |
| BP | GO:0032502; developmental process | GO:0002009; morphogenesis of an epithelium | 3.317E-04 | 9.343E-03 | AR, BCL2, CA2, CA9, ESR1, HIF1A, MET, MMP14, SRC |
| BP | GO:0008152; metabolic process | GO:0018958; phenol-containing compound metabolic process | 3.323E-04 | 9.349E-03 | AKR1B1, BCL2, DRD4, MAOA, TYR |
| BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 3.385E-04 | 9.499E-03 | ADORA1, ADORA2A, ADORA3, APP, AR, BCL2, CDK6, CYP1B1, LMNA, NOX4, PKN1, PTGS2, TERT, TP53, XDH |
| BP | GO:0032501; multicellular organismal process | GO:1903708; positive regulation of hemopoiesis | 3.414E-04 | 9.559E-03 | AXL, CA2, HIF1A, MAPK14, MMP14, SYK, THPO |
| BP | GO:0065007; biological regulation | GO:0032431; activation of phospholipase A2 activity | 3.464E-04 | 9.559E-03 | NMUR2, PLA2G1B |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 3.464E-04 | 9.559E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 3.464E-04 | 9.559E-03 | ADRA2A, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 3.464E-04 | 9.559E-03 | TNKS, TNKS2 |
| BP | GO:0051179; localization | GO:1901529; positive regulation of anion channel activity | 3.464E-04 | 9.559E-03 | ABCB1, CFTR |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.464E-04 | 9.559E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 3.464E-04 | 9.559E-03 | ESR1, ESR2 |
| MF | GO:0005488; binding | GO:0032795; heterotrimeric G-protein binding | 3.464E-04 | 9.559E-03 | ADORA1, ADRA2A |
| MF | GO:0005488; binding | GO:0051425; PTB domain binding | 3.464E-04 | 9.559E-03 | APP, INSR |
| MF | GO:0005488; binding | GO:0005497; androgen binding | 3.464E-04 | 9.559E-03 | ALDH1A1, AR |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 3.540E-04 | 9.745E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.869E-21 | 1.767E-17 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.448E-16 | 2.812E-13 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CFTR |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 2.611E-14 | 1.015E-11 | ADORA1, ADORA2A, ADRA2A, AURKB, BCL2, CA2, CA7, CD38, CDK6, CFTR, HIF1A, HTT, KDR, MAPK1, MAPK14, NEK2, NPC1, NPSR1, PARP1, PLA2G1B, PTGS2, SRC, SYK, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.099E-13 | 3.520E-11 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; SRC |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Diffuse large B-cell lymphoma | C83.3 | PIK3CG |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| J00-J99: Diseases of the respiratory system | Bronchodilator | J45 | CHRM4 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; AKT1; MET; CSNK2A1; ABCB1; SYK; PIK3CG; CA1; FLT3; FLT3; CA9; MMP2; ACHE; DNMT1; PTGS2; SRC; IGF1R; PTK2; GSK3B; ADORA3; HIF1A; CDK1; MAPK1; MAPK14; MMP9; NFKB1; PIM1; PARP1; CD38; BCL2; BCL2; TP53; ESR1; ESR1; KDR; APP |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
| A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | MAPK14 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; MMP1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnosing bronchial hyperreactivity | W88 | CHRM3 |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; ADORA1 |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; ACHE; CYP3A4 |
| NA: NA | Angioedema | NA | PIK3CG |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | CHRM4 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PTGS2 |
| C00-D49: Neoplasms | Endometrial cancer | C54.1 | PIK3CG; PIK3CG |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; ADORA1; ESR1; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | CHRM1 |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1 |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | CHRM5; PTGS2; PTGS2; PTGS2; PTGS2; ESR1 |
| NA: NA | Dystonia | NA | CHRM1 |
| NA: NA | Dysuria | NA | CHRM4 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; MYLK; CA2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| NA: NA | Moderate and severe psychomotor agitation | NA | CHRM4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; CHRM1; CHRM2; CHRM3; CHRM4; INSR; MAPT; ACHE; ACHE; ACHE; PTGS2; GSK3B; ADRA2C; APP |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; SYK; ALOX5; ADORA1 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | CHRM5; PLA2G1B; ESRRA; ADORA2A; ADRA2C |
| C00-D49: Neoplasms | AML | NA | FLT3; KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Amnesia | F04 | CHRM5 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | CHRM4; ACHE; ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| NA: NA | Extrapyramidal disorders secondary to neuroleptic drug therapy | NA | CHRM1 |
| NA: NA | Excessive sweating | NA | CHRM1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; PIK3CG; PIK3CG |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ADRA2C |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | CHRM1; CHRM2; CHRM3; CHRM5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Postoperative nausea and vomiting | R11 | CHRM3 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; CASP1; ADK |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | CHRM4; ADORA2A; ADORA1; ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1 |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT; FLT3; FLT3; DNMT1; DNMT1; AURKB; TP53; TP53 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; CASP1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | CHRM4 |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; IGF1R; MMP9; TP53; KDR |
| C00-D49: Neoplasms | Colon cancer | C50 | ALPL; FLT3 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; MMP13; SYK; PIK3CG; MMP12; PTGS2; ALOX5; MAPK14 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; ADORA3; KDR |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1; PIK3CG |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; SRC; AURKB; CD38; TP53 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1; ESR1 |
| NA: NA | Addiction | NA | CHRM2 |
| NA: NA | Acute respiratory distress syndrome | NA | MAPK14 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; ABCB1; DNMT1; PTGS2; IGF1R; IGF1R; AXL; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; ADORA1; ESR1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | MAPK14; MAPK14 |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK |
| H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; IGF1R; ESR1; ESR1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| NA: NA | HIV infections | NA | AHR |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | MAPK14 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Seborrhea | L21 | CHRM3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | CHRM1; CHRM1; CHRM1; CHRM5; ESRRA; DRD4 |
| NA: NA | Male hypogonadism | NA | AR |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| NA: NA | Schizoaffective disorders | NA | CHRM1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ESRRA; SYK; CASP1; MMP3; PTGS2; PTGS2; PTGS2; PTGS2; ALOX5; MAPK14; TYR; MMP1 |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2; MAPK14 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | DNMT1; PTK2; TP53 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT; IGF1R; KDR |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; INSR; PIK3CG; PIK3CG; CA9; HIF1A; BCL2 |
| A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TERT; TP53; KDR; KDR |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; CHRM2; ADORA1; XDH; ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; CHRM1; CHRM1; CHRM2; CHRM4; ACHE; ADORA2A; ADORA1 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | MAPK14 |
| NA: NA | Abdominal stomach pain | NA | CHRM1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA; MMP2; ESR1 |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | CHRM4; CHRM4 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; CHRM4; PKM; ABCB1; SYK; PIK3CG; FLT3; CA9; MMP2; MMP14; SRC; IGF1R; PTK2; AURKB; HIF1A; MAPK1; MMP9; TP53; KDR; KDR; KDR; TOP2A |
| NA: NA | Spasms | NA | CHRM3 |
| C00-D49: Neoplasms | Soft tissue sarcoma | C00-D49 | DNMT1 |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; ADORA3 |
| I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | CHRM1; CHRM1; CHRM4; CHRM4; CHRM5 |
| NA: NA | Gastritis | NA | CHRM4 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | CHRM4; CHRM4; ESRRA |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1; PIK3CG; CYP2C9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Sjogren's syndrome | M35.0 | CHRM3 |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; CHRM2; PIK3CG; KDR |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| NA: NA | Inflammatory diseases | NA | MAPK14 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; MAPK14 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| NA: NA | GIST | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CHRM1; CHRM3; CHRM4; CA1; CA1; ACHE; ADORA3; ADORA2A; ADORA1; ADRA2C |
| NA: NA | Geographic retinal atrophy | NA | APP |
| C00-D49: Neoplasms | Glioma | C71 | PIK3CG; KDR; APP |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | DNMT1; SRC |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; PTGS2; XDH |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| NA: NA | Uveitis | NA | CHRM4 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | DNMT1; DNMT1; KDR |
| H00-H59: Diseases of the eye and adnexa | Mydriasis diagnosis | H57.0 | CHRM4 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | CHRM5; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Central and peripheral nervous diseases | G96.9 | CHRM4; CHRM5 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
| NA: NA | Enthesopathy | NA | PIK3CG |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; CHRM1; CHRM3; CHRM4; CHRM5; MMP12; MMP12; ALOX5; ADORA2A; MAPK14 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; TYR |
| NA: NA | Vomiting | NA | CHRM4 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Visceral spasms | R25.2 | CHRM1 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
| H00-H59: Diseases of the eye and adnexa | Produce mydriasis and cycloplegia for diagnostic purposes | H57.04 | CHRM4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; INSR; PTPN1; GSK3B; ADORA1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; SRC; ESR1 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PIK3CG; MMP3; PARP1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | CHRM2; CHRM4 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | PIK3CG; KDR |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; KDR |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; TERT; PIK3CG; FLT3; BCL2; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | CHRM1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR; PTPN1; PTPN1; PIK3CG; PIK3CG; PTGS2; NFKB1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | CHRM3; ALOX5 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nocturia | R35 | CHRM4 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; CHRM1; PTGS2; PTGS2; ADORA2A; ADORA1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | CHRM1; CHRM5; ADRA2C; NPSR1; ESR1; APP |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
| C00-D49: Neoplasms | Melanoma | C43 | TERT; PARP1; TYR; KDR; KDR |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
| NA: NA | Menopausal disorder | NA | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Urinary retention | R33 | CHRM4 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| NA: NA | Urgency | NA | CHRM4 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; ESRRA |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK; PIK3CG; PIK3CG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3; BCL2; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; ALOX5; MAPK14; BCL2 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR; SYK; ADORA1; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| J00-J99: Diseases of the respiratory system | Obstructive lung diseases | J40-J44, J47 | CHRM3 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; TERT; SRC; IGF1R; CD38; BCL2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B; ADORA2A |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | CHRM2; PLA2G1B; ESRRA; SYK; SYK; MMP12; PTGS2; ALOX5; ALOX5; ADORA2A; ADORA1; ADRA2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ESRRA; PIK3CG; PTGS2; PTGS2; ALOX5; MAPK14; MMP1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; ALOX5; ADORA3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Organophosphate poisoning | T60.0 | CHRM4 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP13; MMP3; MMP2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; ALOX5 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Acquired nystagmus | H55 | CHRM4 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK; BCL2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
| N00-N99: Diseases of the genitourinary system | Overactive bladder | N32.81 | CHRM3 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; ABCB1; MMP2; PARP1; KDR; KDR; KDR; KDR |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | CHRM1; CHRM3; CHRM4 |
| NA: NA | Functional bowel syndrome | NA | CHRM1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; PARP1 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | CHRM1; CHRM5; MAPT; ACHE; ADORA1 |
| K00-K95: Diseases of the digestive system | Colitis | K50-K52 | CHRM5 |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; CHRM3; INSR; PKM; MMP13; ADK; ACHE; PTGS2; PTGS2; PTGS2; PTGS2; IGF1R; ADORA2A; CDK1; ADRA2C; ADRA2A; ESR1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; TERT; FLT3; MMP2; PTGS2; KDR |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | CHRM1; CHRM2; CHRM4; CHRM4; CHRM4; ADRA2C |
| NA: NA | Peptic ulcer disease | NA | CHRM4 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; CHRM4; ADRA2C |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; KDR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | SYK; ALOX5 |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | CHRM4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | CHRM4 |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| NA: NA | Suprapubic pain | NA | CHRM4 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Stabilize muscle contractions | M00-M99 | CHRM2 |
| K00-K95: Diseases of the digestive system | Stomach ulcer | K25-K27 | CHRM1; CHRM5 |
| G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; TERT; INSR; CYP19A1; PIK3CG; FLT3; FLT3; CA9; IGF1R; CDK1; BCL2; ESR1; ESR1; KDR; KDR; KDR |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT; SRC; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Brain diseases | G00-G99 | CHRM5 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |